Early Remote At-risk Diagnosis for Cerebral Palsy in Follow-up Clinics for High-risk Infants
NCT ID: NCT04287166
Last Updated: 2025-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
100 participants
OBSERVATIONAL
2020-08-03
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The most accurate method to detect and predict CP at an early age is the General Movement Assessment (GMA). GMA is based upon expert observations of infant spontaneous movements in a video. In Central-Norway such expertise is today only present at St. Olavs Hospital, Trondheim University Hospital. Video recordings by health personnel and parents will be used in follow-up programs within CNRHA for remote expert based GMA. In addition, machine learning models will be applied for automatic detection of CP.
Early identification of CP will lead to improved function and increased possibility to direct health care resources to the patients who need it most, independent of geographical and expert based constraints.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Risk Factors , Types and Neuroimaging Findings in Patients With Cerebral Palsy at Assiut University Children's Hospital
NCT06928012
Neuroimaging of Babies During Natural Sleep to Assess Typical Development and Cerebral Palsy
NCT06396520
Early Identification of Infants at Risk of Cerebral Palsy
NCT03211533
GMA and Peri in Moderate-late Preterms
NCT04073836
Assessing Intellectual and Motor Outcomes in High-risk Infants
NCT06857539
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at high-risk for adverse neurological outcomes as considered by the pediatrician on the basis of clinical judgement (example: serious asphyxia, prematurity, stroke, brain hemorrhage)
Exclusion Criteria
* iatrogenic restricted movements (e.g. cast for clubfoot)
0 Months
2 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alesund Hospital
OTHER
Helse Nord-Trøndelag HF
OTHER
St. Olavs Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lise Støylen
Role: STUDY_DIRECTOR
St Olavs Hospital, Clinic of Clinical Services
Torstein Rø IKOM
Role: STUDY_DIRECTOR
Norwegian University of Science and Technology, IKOM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Pediatrics, Møre and Romsdal Hospital Trust
Ålesund, , Norway
Department of Pediatrics, Nord-Trøndelag Hospital Trust
Levanger, , Norway
Department of Pediatrics, St. Olav's Hospital Trust
Trondheim, , Norway
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Adde L, Aberg KB, Fjortoft T, Grunewaldt KH, Lade R, Osland S, Piegsa F, Sandstrom PG, Stoen R, Storvold GV, Eriksen BH. Implementation of remote general movement assessment using the in-motion instructions in a high-risk norwegian cohort. BMC Pediatr. 2024 Jul 10;24(1):442. doi: 10.1186/s12887-024-04927-4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REK 62240
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.